Shanmugam K, Nirmala A, Parthiban P, Pitchiah Kumar M, Dhanam C, Ganesh S, Babu K, Salaikarthikaiyan T
Department of Indian Medicine & Homeopathy, Government of Tamil Nadu, India.
Govt.Medical College & ESI Hospital, Singanallur, Coimbatore, Tamilnadu, India.
J Ayurveda Integr Med. 2022 Jul-Sep;13(3):100597. doi: 10.1016/j.jaim.2022.100597. Epub 2022 Jun 3.
The use of complementary and alternative medicine (CAM) therapies has surged since the spread of COVID-19 pandemic. However, the efficacy and safety of these CAM therapies remains majorly unexplored.
To understand the efficacy and safety of Nochi Kudineer Chooranam (5 gm), Mahasudarsan Chooranam (3 gm) , Adathodai Manapagu (10 ml), Omatheeneer (10 ml), Maldevi chenduram (100 mg) with honey in management of COVID 19 patients.
We conducted a randomised, controlled, open label trial in patients hospitalized with SARS-CoV-2 infection who had an oxygen saturation of 90% or more while breathing ambient air. Patients were randomized into two groups in a 1:1 ratio to either intervention group, receiving seven days of siddha medicine (Intervention group; n = 50) or standard care (control group; n = 50). The primary end point was clinical markers and patient recovery status on day 8.
A total of 100 patients with confirmed COVID-19 with average age of 37 yrs (interquartile range, 28-49) participated in the study. There was no statistically difference between groups at baseline (P > 0.05). After intervention, patients in the intervention group had statistically (P < 0.05) significant reduction in the symptoms when compared to standard care. By end of the intervention period, 6 patients (12%) were hospitalized in the control group and none of them were reported for intervention group.
Among patients with mild to moderate COVID-19, 7 days of siddha medicine showed a significant reduction in the clinical symptoms and requirement of hospitalisation, with no adverse events. Therefore, the particular siddha medicine preparation could be used safely and effectively for the management of COVID-19 patients.
自新冠疫情蔓延以来，补充和替代医学（CAM）疗法的使用激增。然而，这些补充和替代医学疗法的疗效和安全性在很大程度上仍未得到探索。
了解诺奇苦地尼尔丸（5克）、大苏达山丸（3克）、鸭嘴花制剂（10毫升）、奥马提尼尔（10毫升）、马尔德维钦杜拉姆（100毫克）加蜂蜜用于治疗新冠患者的疗效和安全性。
我们对因感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）而住院、在呼吸环境空气时血氧饱和度为90%或更高的患者进行了一项随机、对照、开放标签试验。患者按1:1比例随机分为两组，分别为干预组，接受七天的悉达医学治疗（干预组；n = 50）或标准护理（对照组；n = 50）。主要终点是第8天的临床指标和患者恢复状况。
共有100例确诊新冠患者参与研究，平均年龄37岁（四分位间距，28 - 49岁）。两组在基线时无统计学差异（P > 0.05）。干预后，与标准护理相比，干预组患者的症状有统计学意义的显著减轻（P < 0.05）。到干预期结束时，对照组有6例患者（12%）住院，干预组无住院报告。
在轻度至中度新冠患者中，七天的悉达医学治疗显示临床症状显著减轻且住院需求降低，无不良事件。因此，这种特定的悉达医学制剂可安全有效地用于新冠患者的治疗。
